(Q36402580)

14 August 2017

1 reference

title

Peptide-based molecules in angiogenesis (English)

1 reference

14 August 2017

Luca Domenico D'Andrea

1

1 reference

14 August 2017

Annarita Del Gatto

2

1 reference

14 August 2017

Carlo Pedone

3

1 reference

14 August 2017

Ettore Benedetti

4

1 reference

14 August 2017

1 February 2006

1 reference

Chemical Biology and Drug Design

14 August 2017

1 reference

14 August 2017

67

1 reference

14 August 2017

115-126

1 reference

14 August 2017

2

1 reference

Angiogenesis in health and disease

14 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1747-0285.2006.00356.X

Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1747-0285.2006.00356.X

Angiogenesis in cancer and other diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1747-0285.2006.00356.X

Vascular-specific growth factors and blood vessel formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1747-0285.2006.00356.X

Tumorigenesis and the angiogenic switch

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1747-0285.2006.00356.X

Specialization of tumour vasculature

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1747-0285.2006.00356.X

Molecular mechanisms of coronary collateral vessel growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1747-0285.2006.00356.X

Vascular endothelial growth factor (VEGF) induces remodeling and enhances TH2-mediated sensitization and inflammation in the lung.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1747-0285.2006.00356.X

Angiogenesis modulation in cancer research: novel clinical approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1747-0285.2006.00356.X

Tumor targeting with a selective gelatinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1747-0285.2006.00356.X

VEGF: an update on biological and therapeutic aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1747-0285.2006.00356.X

The biology of VEGF and its receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1747-0285.2006.00356.X

The biology of vascular endothelial growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1747-0285.2006.00356.X

Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1747-0285.2006.00356.X

Vascular endothelial growth factor stimulates tyrosine phosphorylation and recruitment to new focal adhesions of focal adhesion kinase and paxillin in endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1747-0285.2006.00356.X

Vascular endothelial growth factor: crystal structure and functional mapping of the kinase domain receptor binding site

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1747-0285.2006.00356.X

Crystal structure of the complex between VEGF and a receptor-blocking peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1747-0285.2006.00356.X

Solution structure of a phage-derived peptide antagonist in complex with vascular endothelial growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1747-0285.2006.00356.X

Crystal structure at 1.7 A resolution of VEGF in complex with domain 2 of the Flt-1 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1747-0285.2006.00356.X

Identification of vascular endothelial growth factor determinants for binding KDR and FLT-1 receptors. Generation of receptor-selective VEGF variants by site-directed mutagenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1747-0285.2006.00356.X

Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1747-0285.2006.00356.X

Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1747-0285.2006.00356.X

VEGF-Trap: a VEGF blocker with potent antitumor effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1747-0285.2006.00356.X

Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1747-0285.2006.00356.X

Novel peptides selected to bind vascular endothelial growth factor target the receptor-binding site

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1747-0285.2006.00356.X

Identification of a peptide blocking vascular endothelial growth factor (VEGF)-mediated angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1747-0285.2006.00356.X

Arginine-rich anti-vascular endothelial growth factor peptides inhibit tumor growth and metastasis by blocking angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1747-0285.2006.00356.X

Vascular endothelial growth factor (VEGF) receptor II-derived peptides inhibit VEGF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1747-0285.2006.00356.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1747-0285.2006.00356.X

Function and interactions of integrins

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1747-0285.2006.00356.X

Signaling through focal adhesion kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1747-0285.2006.00356.X

Integrin-mediated signal transduction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1747-0285.2006.00356.X

Apoptosis of adherent cells by recruitment of caspase-8 to unligated integrins

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1747-0285.2006.00356.X

Crystal structure of the extracellular segment of integrin alpha Vbeta3

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1747-0285.2006.00356.X

Crystal structure of the extracellular segment of integrin alpha Vbeta3 in complex with an Arg-Gly-Asp ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1747-0285.2006.00356.X

Cell attachment activity of fibronectin can be duplicated by small synthetic fragments of the molecule

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1747-0285.2006.00356.X

Identification and in vivo efficacy of small-molecule antagonists of integrin alphavbeta3 (the vitronectin receptor).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1747-0285.2006.00356.X

Nanomolar small molecule inhibitors for alphav(beta)6, alphav(beta)5, and alphav(beta)3 integrins

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1747-0285.2006.00356.X

N-Methylated cyclic RGD peptides as highly active and selective alpha(V)beta(3) integrin antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1747-0285.2006.00356.X

Arg-Gly-Asp constrained within cyclic pentapeptides. Strong and selective inhibitors of cell adhesion to vitronectin and laminin fragment P1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1747-0285.2006.00356.X

Solid-phase synthesis of cyclic RGD-furanoid sugar amino acid peptides as integrin inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1747-0285.2006.00356.X

Alpha v integrins as receptors for tumor targeting by circulating ligands.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1747-0285.2006.00356.X

Disintegrins: a family of integrin inhibitory proteins from viper venoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1747-0285.2006.00356.X

Immunological characterization of eristostatin and echistatin binding sites on alpha IIb beta 3 and alpha V beta 3 integrins

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1747-0285.2006.00356.X

Integrin regulation of growth factor receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1747-0285.2006.00356.X

Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1747-0285.2006.00356.X

VEGF gene therapy: stimulating angiogenesis or angioma-genesis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1747-0285.2006.00356.X

99mTc-Labeled Small Peptides as Diagnostic Radiopharmaceuticals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1747-0285.2006.00356.X

A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1747-0285.2006.00356.X

10.1111/J.1747-0285.2006.00356.X

21 January 2018

Identifiers

DOI

1 reference

14 August 2017

1 reference